[Gilead Sciences](https://www.gilead.com)

April 20, 2026 (LOI deadline) | July 3, 2026 (Full proposal deadline)

No fixed maximum; budget must be proportional to scope. Overhead capped at 30%. Typical project duration: 18 months.

Supports research to address unmet medical needs and improve patient outcomes in primary biliary cholangitis (PBC).

Only research from regions where Seladelpar is approved and available is eligible.

--- ## Description This program supports research proposals focused on characterizing and addressing unmet medical needs in primary biliary cholangitis (PBC), a chronic autoimmune liver disease. The initiative seeks to advance understanding of PBC, identify gaps in current clinical approaches, and develop innovative solutions to improve patient outcomes. Proposals should generate data relevant to the PBC community and include plans for dissemination through scientific forums and journals. The program is part of Gilead’s broader commitment to inflammation research. --- ## Due Dates - **April 20, 2026:** Letter of Interest (LOI) submission deadline (closes at 23:59 PST) - **July 3, 2026:** Full proposal submission deadline (for invited applicants; closes at 23:59 PST) Additional timeline milestones: - **May 20, 2026:** Notification of LOI outcome and full proposal invitations - **August 2026:** Notification of full proposal outcome --- ## Funding Amount - No predetermined maximum award amount; budgets must be appropriately proportional to the study's scope. - Overhead costs are capped at 30% of the total budget. - Projects should be designed for completion within 18 months of initiation. Longer studies must be clearly justified. - Funding is for research activities only; routine medical care costs are not eligible. --- ## Eligibility - Open to academic institutions, clinical investigators, community-based organizations, and research networks. - Applicants must be from regions where Seladelpar is approved and commercially available at study initiation. - Proposals should not include direct comparisons across 2L (second-line) treatment products. - The study sponsor is typically the institution employing the principal investigator and must ensure all regulatory and ethical approvals. - Funding cannot be used for patient care, routine medical expenses, honoraria for healthcare providers, or lobbying activities. - Only one sponsor per contract negotiation; funding overlap with other grants must be disclosed and avoided. --- ## Application Process ### Stage 1: Letter of Interest (LOI) - Submit an LOI via the [Gilead OPTICS portal](https://gileadrnd.appiancloud.com/suite/portal/login.jsp) between March 9, 2026 and April 20, 2026. - LOI should include a concise project overview and estimated budget. - LOIs will be reviewed for alignment with RFP aims, scientific rigor, and feasibility. - Top-ranked LOIs will be invited to submit full proposals. ### Stage 2: Full Proposal - Full proposals (upon invitation) are due by July 3, 2026. - Must include a detailed budget and study plan. - Proposals are evaluated on scientific merit, impact, sustainability, and research team capacity. ### Review & Award - Proposals are competitively reviewed by Gilead’s internal committee. - Funding decisions are based solely on merit and alignment with RFP criteria. - Award notification expected by August 2026. --- ## Additional Information - Research topics of interest include: criteria and timing for 2L treatment initiation, barriers to timely 2L treatment, and interventions to address these barriers. - Studies must use all locally-approved 2L treatment options but should not directly compare products. - Results should be disseminated rapidly after study completion. - For questions about eligibility or project scope, contact your local Gilead Medical Science Liaison. --- ## External Links - [Program Details & RFP PDF](https://www.gilead.com/-/media/files/pdfs/research/handle-pbc-2026-rfp.pdf) - [Apply via Gilead OPTICS Portal](https://gileadrnd.appiancloud.com/suite/portal/login.jsp) - [Inflammation RFP Opportunities Overview](https://www.gilead.com/science/research/research-funding-programs/external-sponsored-research/inflammation-rfp-opportunities) - [How to Apply for Funding](https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding) - [Gilead Grant Terms & Conditions](https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/terms-and-conditions) --- ## Contact Information | Type | Details | |---------------------|----------------------------------------------| | General Inquiries | [grants@gilead.com](mailto:grants@gilead.com) | | Phone | +1 (650) 574 3000 | | Online Contact | [Contact Gilead Sciences](https://www.gilead.com/contact-us) | | Medical Science Liaison | Reach out locally for RFP/project questions | ---

PBC: HANDLE 2026

Sign in to see full grant listing